The Distribution of Kell Blood Group Antigens and Phenotypes (K and k) Among Saudi Blood Donors of King Abdulaziz Medical City – Western Region: A Cross-Sectional Study Authors: Hiam O Mulla Published: 2026 ABSTRACT PurposeThe Kell (KEL) blood group system is one of the most clinically significant red blood cell antigens due to the K antigen’s high immunogenicity and involvement in transfusion reactions as well as hemolytic disease of the fetus and newborn (HDFN). This study aims to assess the prevalence of K (KEL1) and k (KEL2) antigens, along with their associated phenotypes, among Saudi blood donors at King Abdulaziz Medical City (KAMC), Jeddah, and to compare findings with regional data in Saudi Arabia.Materials and MethodsThis cross-sectional study included 19,769 Saudi blood donors at KAMC-Jeddah. Using standard immunohematological techniques, donor samples were screened for K and k antigens. Antigen and phenotype frequencies were calculated and compared with published Saudi studies. Statistical analysis was performed to assess differences in antigen and phenotype prevalence between Saudi populations.ResultsThe K antigen was detected in 13.93% of donors, whereas 98.92% expressed the k antigen. The most common KEL phenotype was K–k+, accounting for 86.07% of the population, followed by K+k+ (12.85%) and K+k– (1.07%). The K–k– phenotype was found to be exceedingly rare at 0.005%. Comparative analysis demonstrated statistically significant differences in K antigen prevalence between the current cohort and donor populations from Central (KAMC-Riyadh) and Southwestern (Jazan) regions, whereas no notable variations were observed when compared with Makkah and Jeddah within the Western region. The k antigen remained consistently prevalent across all regions. Notably, this study represents one of the largest cohorts reported in Saudi Arabia and identifies a rare K–k– phenotype within the donor population.ConclusionThis study provides a comprehensive assessment of Kell antigen and phenotypic distribution among Saudi blood donors. By reinforcing regional variation as well as the predominance of the k antigen, the findings offer valuable baseline information to support transfusion practices, particularly for transfusion-dependent populations. Introduction Human red blood cells (RBCs) express a variety of glycoproteins and glycolipids on their surfaces, which are referred to as blood group antigens. These polymorphic antigens, which differ among populations due to genetic and geographic variations, are essential for compatibility in transfusion therapy. For safer transfusion procedures and pregnancy management, it is crucial to determine the prevalence of blood group antigens for the different Saudi Arabian regions specifically due to consanguineous marriages. The danger of immunization responses brought on by antibodies recognizing these antigens can be considerably decreased by increasing awareness of antigen predominance. This approach enables more effective blood management techniques and guarantees better patient outcomes. The Kell blood group system derives its name from “Mrs. Kelleher,” the first individual known to produce an anti-K antibody (anti-KEL1).1 Coombs et al identified this antibody in 1946 after Mrs. Kelleher gave birth to a stillborn baby, due to a condition now recognized as hemolytic disease of fetus and newborn (HDFN).1,2 This was followed by the discovery of the “Cellano”, anti-k (anti-KEL2) antibody, identified in another pregnant woman in 1949 by Levine et al.3 According to the International Society of Blood Transfusion (ISBT), the Kell – referred to as KEL – blood group system comprises 40 antigens present on red blood cells, myeloid progenitor cells, and various other tissues.4–6 It is due to the immunogenic nature of antigens belonging to this system that they are ranked third in significance after the ABO and Rh systems and sixth overall among all 47 blood group systems.7 Extensive molecular studies have provided insights into the Kell gene and its protein structure. The Kell gene, located on chromosome 7q33, is approximately 21.5 Kbp long and has 19 exons.8,9 The highly polymorphic nature of this gene results in various point mutations and amino acid substitutions.10 With a molecular weight of 93 kDa, the Kell protein is a type II single-pass transmembrane glycoprotein.9 There are 47 amino acids in the cytoplasmic region’s N-terminal and 665 amino acids in the extracellular C-terminal.10 Because of its sequence resemblance to neutral zinc-endopeptidase, the Kell glycoprotein serves as a source of bioactive peptides as well as a proteolytic enzyme.11 The KEL1/KEL2 polymorphism is the result of a single nucleotide mutation on exon 6, where cytosine (C) is replaced by thymine (T).8 This change causes an amino acid substitution, converting threonine to methionine and damaging an N-glycosylation site.9 The Kell system’s 40 antigens are divided into high- and low-frequency groups based on their expression rates in individuals. Several of them are antithetical antigens, organized into 20 antithetical pairs, with several additional antigens of low prevalence.4,5 The system’s main antigens are K, k, Kpa, Kpb, Jsa, and Jsb. The most immunogenic component of this system is Anti-K, an IgG antibody capable of causing extravascular hemolysis, which can lead to serious consequences such HDFN and hemolytic transfusion reactions (HTR).2,4 The presence of anti-K antibodies in pregnant women in Saudi Arabia is not entirely uncommon. Bakhali et al reported a case in which a mother with anti-K antibodies, showing alloimmunization against the K (KEL1) antigen, lost her third child two months postpartum.12 This incident was linked to the incompatibility between the fetus’s K-positive red blood cells (RBCs) and the mother’s K-negative erythrocytes. The maternal immune system detected the fetal RBCs as foreign, which resulted in the formation of anti-K antibodies and the unfortunate fatal complications.12 The Kell blood group is one of the most clinically significant systems in transfusion medicine, covering a wide range of antigens. Among these, K (KEL1) and k (KEL2) are the most extensively studied due to their high prevalence and strong immunogenicity.13 Globally, the prevalence of the K (KEL1) antigen varies significantly among populations. Approximately 9% of Caucasians carry the K antigen.7 In Indians, however, its prevalence is at roughly 2%.14 Meanwhile, in East Asia, such as the Chinese Han population, it is extremely uncommon, with a frequency of less than 0.14%.15 In contrast, the k (KEL2) antigen is universally expressed, with a prevalence of more than 99% globally, making it an important focus in compatibility testing, particularly for patients with anti-k antibodies.7 The distribution of K and k antigens exhibits notable variations within the Middle East region. In Oman, a study involving 337 blood donors found the K (KEL1) antigen present in 4.5% of individuals, while the k (KEL2) antigen was present in 99.4%.16 While in Egypt, research indicates that 6.0% of individuals are K (KEL1) antigen-positive, with the k (KEL2) antigen present in 92.3%.17 In Saudi Arabia, extensive studies across provinces such as Makkah, Jeddah, Riyadh, and Jazan report K (KEL1) antigen frequencies ranging from approximately 6.52% to 18.7%.18–21 Meanwhile, the k (KEL2) antigen prevalence remains consistently high, ranging from 96% to 99.28%, underscoring its universality within the Saudi population.18–21 This study’s focus on K (KEL1) and k (KEL2) antigens is motivated by their direct implications for transfusion safety, risk of alloimmunization, and the challenge of sourcing compatible blood for individuals with rare antigen profiles. Accordingly, this study aimed to determine the distribution of K and k antigens and their associated phenotypes among Saudi blood donors at King Abdulaziz Medical City in the Western region. Materials and Methods Selection of Participants and Blood Collection This cross-sectional study was approved by the Institutional Review Board (IRB) of King Abdullah International Medical Research Center (KAIMRC), Jeddah, Saudi Arabia (IRB Approval No. 0000086124). The study was conducted in accordance with the principles of the Declaration of Helsinki. This study included 19,769 anonymous voluntary Saudi citizen regular blood donors from the Makkah Province of Saudi Arabia, who donated blood to King Abdulaziz Medical City (KAMC), National Guard Health Affairs (NGHA), Jeddah, during the period of 2020–2024. Blood was obtained using ethylenediamine tetraacetate (EDTA) tubes only upon completion of a donation questionnaire, agreement to participate in the study, and signing of an informed consent form. There were no missing data for the variables included in this study; therefore, all available records were included in the final analysis. Inclusion Criteria The study comprised only regular voluntary Saudi Arabian residents aged 17 to 65 who donated blood or blood products at the Western-region KAMC, NGHA blood transfusion service centers and met the donor eligibility standards of the American Society for Clinical Pathology International (ASCPi). To be eligible to donate blood, donors had to have a minimum weight of 55 kg, temperature below 37.5°C, and a hemoglobin level over 12.5 g/dL. They also had to have no prior history of liver disease, cancer, or bleeding tendencies, as well as no travel history to areas endemic for malaria, human immunodeficiency virus (HIV), or variant Creutzfeldt-Jakob disease. Additionally, blood donors underwent screening to make sure they tested negative for syphilis, HIV 1 and 2, human T-lymphotropic virus 1 and 2, malaria, hepatitis B virus (HBV), hepatitis C virus (HCV), and other transfusion-transmitted infections. Exclusion Criteria This study did not include non-Saudi Arabian blood donors or Saudi Arabian donors donating blood to transfusion service centers other than Western-region KAMC, NGHA, Jeddah. Furthermore, blood samples that tested positive for any of the aforementioned infectious disorders were also not included. Immunohematological Evaluation Serotyping was performed using a solid phase technique with immuClone® anti-K Galileo Monoclonal IgM (clone/cell line MS56) and immuClone® anti-k Monoclonal IgG (clone\cell line P3A118OL67) blood grouping reagents, as directed by the manufacturer (Immucor Medizinische Diagnostik GmbH, Dreieich, Germany). Positive reactions included agglutination and antibody clumping with K and/or k antigens, indicating the presence of the antigen, whereas negative reactions included a lack of agglutination between antibodies and antigens, indicating the absence of K and/or k antigens in the given sample. This study did not include typing for minor Kell antigens such as Kpa, Kpb, Jsa, and Jsb, as these are not routinely screened in the donor population in KAMC, Jeddah. Statistical Analysis Raosoft’s Sample Size Calculator was used to determine the optimal sample size. With a study population of more than 19,000 blood donors, a minimal sample size of 385 donors was required to maintain a 95% confidence level and a sufficiently accurate margin of error. Antigen frequencies for K and k, as well as the distribution of KEL phenotypes, are shown as percentages in table format. Using RStudio software, the prevalence of KEL antigen was measured using a Chi-square test, while Fisher’s exact test was used to estimate the prevalence of KEL phenotype among various Saudi populations. Significant differences are indicated by P-values of <0.05. Results This study was conducted on 19,769 Saudi blood donors from King Abdulaziz Medical City, Jeddah. All participants were screened for the K (KEL1) and k (KEL2) antigens of the Kell blood group system. The frequencies of these antigens are presented in Table 1. Table 1KEL Antigen Frequencies Among Saudi Arabians at KAMC JeddahAntigenNo.Percentage (%)95% CI (%)K+275313.9313.45–14.41K–1701686.0785.59–86.55k+1955698.9298.78–99.06k–2131.080.94–1.22Abbreviations: CI, Confidence Interval; KAMC, King Abdulaziz Medical City. Table 1KEL Antigen Frequencies Among Saudi Arabians at KAMC JeddahAntigenNo.Percentage (%)95% CI (%)K+275313.9313.45–14.41K–1701686.0785.59–86.55k+1955698.9298.78–99.06k–2131.080.94–1.22Abbreviations: CI, Confidence Interval; KAMC, King Abdulaziz Medical City. KEL Antigen Frequencies Among Saudi Arabians at KAMC Jeddah Abbreviations: CI, Confidence Interval; KAMC, King Abdulaziz Medical City. For the K (KEL1) antigen, 13.93% of donors (n = 2,753) were K-positive, whereas for the k (KEL2) antigen, 98.92% (n = 19,556) were k-positive. The distribution of KEL phenotypes is summarized in Table 2. The most frequent phenotype observed was the homozygous k (KEL2) phenotype (K–k+), accounting for 86.07% of the study population (n = 17,015). This was followed by the heterozygous K+k+ phenotype at 12.85% (n = 2541), and the homozygous K+k– phenotype at 1.07% (n = 212). Only one donor, among the 19769 participants (0.005%), was found to have the phenotype of K–k– (n = 1). Table 2KEL Phenotype Frequencies Among Saudi Arabians at KAMC JeddahPhenotypeNo.Percentage (%)95% CI (%)Kell positiveK+k+254112.8512.38–13.32K+k–2121.070.93–1.21Kell negativeK–k–186.0785.59–86.55K–k+170150.0050.00013–0.028Abbreviations: CI, Confidence Interval; KAMC, King Abdulaziz Medical City. Table 2KEL Phenotype Frequencies Among Saudi Arabians at KAMC JeddahPhenotypeNo.Percentage (%)95% CI (%)Kell positiveK+k+254112.8512.38–13.32K+k–2121.070.93–1.21Kell negativeK–k–186.0785.59–86.55K–k+170150.0050.00013–0.028Abbreviations: CI, Confidence Interval; KAMC, King Abdulaziz Medical City. KEL Phenotype Frequencies Among Saudi Arabians at KAMC Jeddah Abbreviations: CI, Confidence Interval; KAMC, King Abdulaziz Medical City. The distribution of Kell blood group antigens K (KEL1) and k (KEL2) among Saudi blood donors at King Abdulaziz Medical City in Jeddah is presented in Table 3. The k (KEL2) antigen showed a high frequency (98.92%), while the K (KEL1) antigen was observed in 13.93% of donors. Table 3KEL Antigen Prevalence in Saudi Arabia: A Comparison of the Current Study with Related Research Performed in Other Hospitals and RegionsRegionWesternCentralSouthwesternAntigenPercentage of this study; KAMC, NGHA, Jeddah, Saudi Arabia: 19769 participantsPercentage in Makkah, Saudi Arabia: 150 Participants18Percentage in Jeddah, Saudi Arabia: 758 Participants19Percentage in KAMC, NGHA, Riyadh, Saudi Arabia: 400 Participants20Percentage in Jazan, Saudi Arabia: 138 Participants21K (KEL1) positive13.93%18.7%16.3%18.2%6.52%k (KEL2) positive98.92%96%98.5%97%99.28%P-value0.14850.10770.0294*0.03239*Notes: *Significant.Abbreviations: KAMC, King Abdulaziz Medical City; NGHA, National Guard Health Affairs. Table 3KEL Antigen Prevalence in Saudi Arabia: A Comparison of the Current Study with Related Research Performed in Other Hospitals and RegionsRegionWesternCentralSouthwesternAntigenPercentage of this study; KAMC, NGHA, Jeddah, Saudi Arabia: 19769 participantsPercentage in Makkah, Saudi Arabia: 150 Participants18Percentage in Jeddah, Saudi Arabia: 758 Participants19Percentage in KAMC, NGHA, Riyadh, Saudi Arabia: 400 Participants20Percentage in Jazan, Saudi Arabia: 138 Participants21K (KEL1) positive13.93%18.7%16.3%18.2%6.52%k (KEL2) positive98.92%96%98.5%97%99.28%P-value0.14850.10770.0294*0.03239*Notes: *Significant.Abbreviations: KAMC, King Abdulaziz Medical City; NGHA, National Guard Health Affairs. KEL Antigen Prevalence in Saudi Arabia: A Comparison of the Current Study with Related Research Performed in Other Hospitals and Regions Notes: *Significant. Abbreviations: KAMC, King Abdulaziz Medical City; NGHA, National Guard Health Affairs. Comparative analysis across regional studies18–21 demonstrated variations in KEL antigen distribution. Statistically significant differences (P-value <0.05) were observed between the current study and donor populations from the Central region (King Abdulaziz Medical City, Riyadh)20 and the Southwestern region (Jazan).21 In contrast, no statistically significant differences were observed when compared with populations from Makkah18 and Jeddah19 (P-value >0.05). The phenotypic distribution of KEL antigens is shown in Table 4. The K−k+ phenotype was the most prevalent, followed by the heterozygous K+k+ phenotype. Homozygous K positive (K+k−) and K−k− phenotypes were rare findings. Table 4KEL Phenotype Prevalence in Saudi Arabia: A Comparison of the Current Study with Related Research Performed in Other Hospitals and RegionsRegionWesternCentralSouthwesternPhenotypePercentage of this study; KAMC, NGHA, Jeddah, Saudi Arabia: 19769 ParticipantsPercentage in Makkah, Saudi Arabia: 150 Participants18Percentage in Jeddah, Saudi Arabia: 758 Participants19Percentage in KAMC, NGHA, Riyadh, Saudi Arabia: 400 Participants20Percentage in Jazan, Saudi Arabia: 138 Participants21Kell positiveK+k+12.85%10%14.8%15.5%5.8%K+k–1.07%0.7%1.5%3%0.72%Kell negativeK–k–0.005%0.7%0%0%0%K–k+86.07%54%83.7%81.5%93.48%P-value0.01152*0.18180.002636*0.03493*Notes: *Significant.Abbreviations: ISBT, International Society of Blood Transfusion; KAMC, King Abdulaziz Medical City; NGHA, National Guard Health Affairs; RBCs, Human red blood cells. Table 4KEL Phenotype Prevalence in Saudi Arabia: A Comparison of the Current Study with Related Research Performed in Other Hospitals and RegionsRegionWesternCentralSouthwesternPhenotypePercentage of this study; KAMC, NGHA, Jeddah, Saudi Arabia: 19769 ParticipantsPercentage in Makkah, Saudi Arabia: 150 Participants18Percentage in Jeddah, Saudi Arabia: 758 Participants19Percentage in KAMC, NGHA, Riyadh, Saudi Arabia: 400 Participants20Percentage in Jazan, Saudi Arabia: 138 Participants21Kell positiveK+k+12.85%10%14.8%15.5%5.8%K+k–1.07%0.7%1.5%3%0.72%Kell negativeK–k–0.005%0.7%0%0%0%K–k+86.07%54%83.7%81.5%93.48%P-value0.01152*0.18180.002636*0.03493*Notes: *Significant.Abbreviations: ISBT, International Society of Blood Transfusion; KAMC, King Abdulaziz Medical City; NGHA, National Guard Health Affairs; RBCs, Human red blood cells. KEL Phenotype Prevalence in Saudi Arabia: A Comparison of the Current Study with Related Research Performed in Other Hospitals and Regions Notes: *Significant. Abbreviations: ISBT, International Society of Blood Transfusion; KAMC, King Abdulaziz Medical City; NGHA, National Guard Health Affairs; RBCs, Human red blood cells. Statistical analysis of phenotypic distribution revealed significant differences between the current study and Makkah18 (P-value <0.05), as well as the Central region (Riyadh)20 (P-value <0.01), and the Southwestern region (Jazan)21 (P-value <0.05). No statistically significant difference was observed when compared with the previous study conducted in Jeddah19 (P-value >0.05). Discussion This study assessed the distribution of Kell blood group antigens among Saudi blood donors at King Abdulaziz Medical City in Jeddah and compared the findings with previously reported data from different regions of Saudi Arabia. The predominance of the k (KEL2) antigen observed in this cohort is consistent with its well-established high frequency across diverse national populations.18–21 Notably, this study represents one of the largest cohorts reported in Saudi Arabia and identifies a rare K−k− phenotype within the donor population, providing novel insight into Kell antigen distribution in the Western region. Several regional studies conducted across Saudi Arabia have reported variability in Kell antigen distribution, which may reflect underlying genetic diversity, population structure, and regional demographic differences. In Makkah, a study involving 150 donors reported a K antigen prevalence of 18.7% and a k antigen prevalence of 96%.18 In Jeddah, among 758 donors, the most frequent Kell phenotype was Kp(a−b+), followed by K−k+ and K+k+19 In the Central region (King Abdulaziz Medical City, Riyadh), analysis of 400 donors demonstrated K and k antigen prevalences of 18.2% and 97%, respectively.20 In contrast, the Southwestern region (Jazan) reported a lower K antigen prevalence of 6.52% and a k antigen prevalence of 99.28% among 138 donors.21 In interpreting regional differences, comparisons within the Western region (Makkah and Jeddah) did not demonstrate statistically significant variation, likely reflecting shared geographic and demographic characteristics. In contrast, differences observed with the Central (Riyadh) and Southwestern (Jazan) regions support the presence of regional variation in Kell antigen distribution. The phenotypic distribution observed is consistent with the autosomal codominant inheritance of the Kell blood group system and reinforces the predominance of the k antigen across studied populations. Although variability was observed across regions, most of these studies were limited by relatively small sample sizes. A key strength of the present study is the inclusion of over 19,000 donors collected over a four-year period, providing a more robust and representative evaluation of Kell antigen distribution in the Western region. Clinically, the high immunogenicity of the K antigen is associated with an increased risk of alloimmunization, hemolytic transfusion reactions, and HDFN, underscoring its importance in transfusion practice.22,23 Of particular importance is the identification of the rare K−k− phenotype in this study. Individuals with this phenotype are of high transfusion relevance due to the potential presence of anti-K antibodies, which can make compatible blood extremely difficult to source. Although the corresponding sample was cryopreserved, the donor was not available for repeat donation, highlighting challenges in maintaining access to rare donor units. Currently, there is no established national rare blood donor registry in Saudi Arabia, and the absence of such infrastructure may limit the availability of compatible blood for alloimmunized patients requiring rare phenotypes. This study has several limitations. The analysis was restricted to K and k antigens, without inclusion of other clinically relevant Kell system antigens such as Kpa, Kpb, Jsa, and Jsb. Additionally, the study was conducted at a single center, which may limit full national representation despite the large sample size. Future studies should focus on extended Kell phenotyping, incorporation of molecular genotyping approaches, and expansion to multicenter or nationwide cohorts to better characterize antigen distribution across the Saudi population. Establishing a national rare donor registry, along with structured donor follow-up and cryopreservation strategies, is strongly recommended to improve transfusion support for patients with rare blood group requirements. While the findings are most directly applicable to the Western region, the large sample size and consistency with regional data suggest that they may be broadly representative of the Saudi population, with consideration of regional demographic variation. Conclusion The prevalence of the K–k+ phenotype and the low frequency of K-positive individuals emphasize the importance of matching for KEL antigens from a transfusion medicine perspective, particularly in Saudi Arabia, where transfusion-dependent hemoglobinopathies such as sickle cell disease and thalassemia are common.24 By leveraging a large-scale dataset of over 19,000 individuals collected over four years, this study provides valuable baseline data to support the development of national transfusion policies and optimized donor selection strategies. These findings contribute to a clearer understanding of Kell antigen distribution within the Saudi population and underscore the need for expanded antigen profiling, including minor Kell antigens (Kpa, Kpb, Jsa, and Jsb), in future studies to further enhance transfusion safety and compatibility.